$57.43
AtriCure


Performance
Dividends
1W
1M
YTD
1Y
3Y
About
AtriCure is a medical device company that provides innovative solutions designed to decrease the global Afib epidemic.
Twitter
Web
Share
18/36
Growth
Score
10/36
Dividend
Score
Valuation
PE Ratio
53.5
PS Ratio
9.62
3
RSI
43.95
0
PEG Ratio
-0.01
3
PRG Ratio
0.35
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
92.24%
3
Gross Margin
75.04%
3
Current Ratio
3.47
Return on Assets
8.16%
Return on Equity
11.48%
Return on inv. Capital
29.13%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2021 274.33M
2014
2015
2016
2017
2018
2019
2020
2021
7
Net Income 2021 50.20M
2014
2015
2016
2017
2018
2019
2020
2021
7
Gross Profit 2021 205.86M
2014
2015
2016
2017
2018
2019
2020
2021
7
What will move the market
These are the numbers that will move the market, and the guidance that will move it as well.
-$0.32
100.16% YoY
EPS
71.17M
20.10% YoY
Revenue
Current Quarter Analyst Estimates
-$0.28
100.22% YoY
EPS
80.34M
12.60% YoY
Revenue
Next Quarter Analyst Estimates
About
Sector/Industry
Healthcare
Medical Instruments & Supplies
IPO Date
05.08.2005
MaketCap
2.65B
Country
US
CEO
Mr. Michael Carrel
Description
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Updated 15.03.2022